Tipsheet
What matters at India’s listed companies
Earnings · Pharmaceuticals · Micro cap

Hemo Organic's revenue fell 63%. Its auditors can't confirm the books.

The specialty-chemicals nano-cap swung to a full-year loss as revenue fell to ₹93.10 lakh. Auditors issued a qualified opinion, and management wrote off all deferred tax assets.


Mkt cap₹6.97 cr
ROE0.00%
₹77.81 lakh Net loss for FY26, a reversal from a ₹16.39 lakh profit in FY25.

What's new

  • Annual revenue fell to ₹93.10 lakh from ₹248.42 lakh, a drop of over 60%.
  • The company posted a full-year net loss of ₹77.81 lakh, swinging from a profit.
  • Auditors qualified their report over missing balance confirmations; management reversed all deferred tax assets.

Why this matters

A qualified audit opinion means the financials come with a warning label: the numbers for receivables, payables, and loans are not independently verified. Combined with a 63% revenue collapse and a full write-off of future tax benefits, the filing paints a picture of a company whose operational and accounting foundations are crumbling.

What we're watching

  • Whether the qualified opinion escalates to an adverse one in FY27 if records aren't fixed.
  • The impact of the recent warrant allotment on the depleted share capital base.
  • If the revenue slide continues, Hemo Organic risks hitting SEBI's net-worth thresholds.

The full read

Hemo Organic is shrinking fast. Revenue fell to ₹93.10 lakh from ₹248.42 lakh in FY26, a drop of over 60%. The company swung from a ₹16.39 lakh profit to a ₹77.81 lakh loss.

Its auditors aren't comfortable with the books either. They issued a qualified opinion because they could not get balance confirmations for trade receivables, payables, and loans. Management, meanwhile, wrote off ₹27.93 lakh in deferred tax assets, conceding it doesn't expect to make taxable profits again soon. The recent warrant allotment provides a cash buffer, but the fundamentals are worsening. With revenue at these levels, the company is barely covering its administrative costs.

Questions answered

How much did revenue fall, and what was the full-year loss?
Revenue fell to ₹93.10 lakh from ₹248.42 lakh the prior year. The company posted a net loss of ₹77.81 lakh, swinging from a ₹16.39 lakh profit in FY25.
What did the auditors say, and why does it matter?
The statutory auditors issued a qualified opinion because they could not get balance confirmations for trade receivables, payables, and loans. This means the figures for those items are not independently verified, raising questions about the quality of the accounts.
Why did management reverse all deferred tax assets?
Management fully reversed ₹27.93 lakh in deferred tax assets, acknowledging persistent operating losses and uncertainty over generating future taxable profits. The move removes a balance-sheet item that depended on a recovery that management no longer expects.
Is this a new problem, or a deepening one?
The qualified audit opinion is a recurring issue, indicating ongoing deficiencies in record-keeping. This year, the operational collapse makes the accounting weakness more acute and harder to ignore.
Mentioned: Hemo Organic Ltd · ₹77.81 lakh net loss · FY26 audited results
Primary source BSE · NSE · Tijori

An independent reading of the company's own disclosure — the primary filing above is the final word.

Company snapshot

Hemo Organic Ltd.

Pharmaceuticals
₹7 cr

Latest quarter · Mar 2026

Sales₹1 cr
Net profit−₹1 cr
Op. margin−32.0%
EPS−₹1.46

Strength & growth

Debt / equity-9.77×
Current ratio1.29×
Sales CAGR+23.8%